EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias

Methasit Jaisa-Aad, Clara Muñoz-Castro, Molly A Healey, Bradley T Hyman, Alberto Serrano-Pozo iD

Acta Neuropathologica · 2024

DOI: 10.1007/s00401-024-02712-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2024. Verfasst von Methasit Jaisa-Aad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Frontotemporal Dementia, Lewy Body Disease. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging, Real Colegio Complutense at Harvard University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reactive astrogliosis accompanies the two neuropathological hallmarks of Alzheimer’s disease (AD)—Aβ plaques and neurofibrillary tangles—and parallels neurodegeneration in AD and AD-related dementias (ADRD). Thus, there is growing interest in developing imaging and fluid biomarkers of reactive astrogliosis for AD/ADRD diagnosis and prognostication. Monoamine oxidase-B (MAO-B) is emerging as a target for PET imaging radiotracers of reactive astrogliosis. However, a thorough characterization of MAO-B expression in postmortem control and AD/ADRD brains is lacking. We sought to: (1) identify the primary cell type(s) expressing MAO-B in control and AD brains; (2) quantify MAO-B immunoreactivity in multiple brain regions of control and AD donors as a proxy for PET radiotracer uptake; (3) correlate MAO-B level with local AD neuropathological changes, reactive glia, and cortical atrophy; (4) determine whether the MAOB rs1799836 SNP genotype impacts MAO-B expression level; (5) compare MAO-B immunoreactivity across AD/ADRD, including Lewy body diseases (LBD) and frontotemporal lobar degenerations with tau (FTLD-Tau) and TDP-43 (FTLD-TDP). We found that MAO-B is mainly expressed by subpial and perivascular cortical astrocytes as well as by fibrous white matter astrocytes in control brains, whereas in AD brains, MAO-B is significantly upregulated by both cortical reactive astrocytes and white matter astrocytes across temporal, frontal, and occipital lobes. By contrast, MAO-B expression level was unchanged and lowest in cerebellum. Cortical MAO-B expression was independently associated with cortical atrophy and local measures of reactive astrocytes and microglia, and significantly increased in reactive astrocytes surrounding Thioflavin-S+ dense-core Aβ plaques. MAO-B expression was not affected by the MAOB rs1799836 SNP genotype. MAO-B expression was also significantly increased in the frontal cortex and white matter of donors with corticobasal degeneration, Pick’s disease, and FTLD-TDP, but not in LBD or progressive supranuclear palsy. These findings support ongoing efforts to develop MAO-B-based PET radiotracers to image reactive astrogliosis in AD/ADRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseFrontotemporal DementiaLewy Body DiseaseHumansGliosisBiomarkersAtrophy

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid plaquesAstrocyteMonoamine oxidase-BNeurofibrillary tanglesPositron emission tomography

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • MassGeneral Institute for Neurodegenerative Disease, 114 16th St., Charlestown, MA, 02129, USA.
  • Harvard Medical School, Boston, MA, 02115, USA.
  • Massachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.
  • Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA. aserrano1@mgh.harvard.edu.
  • MassGeneral Institute for Neurodegenerative Disease, 114 16th St., Charlestown, MA, 02129, USA. aserrano1@mgh.harvard.edu.

ORCID-Profile: Alberto Serrano-Pozo

Förderung

  • NIA NIH HHS
  • National Institute on Aging
  • Real Colegio Complutense at Harvard University
  • Prince Mahidol Award Youth Program
  • Martin L. and Sylvia Seevak Hoffman Fellowship for Alzheimer's Research
  • Karen Toffler Charitable Trust
  • Harrison Gardner Jr. Innovation Award

Zitieren

APA

Jaisa-Aad, M., Muñoz-Castro, C., Healey, M. A., Hyman, B. T., & Serrano-Pozo, A. (2024). Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02712-2

Vancouver

Jaisa-Aad M, Muñoz-Castro C, Healey MA, Hyman BT, Serrano-Pozo A. Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias. Acta Neuropathologica. 2024. doi:10.1007/s00401-024-02712-2

BibTeX
@article{JaisaAad2024,
  author = {Jaisa-Aad, Methasit and Muñoz-Castro, Clara and Healey, Molly A and Hyman, Bradley T and Serrano-Pozo, Alberto},
  title = {Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias},
  journal = {Acta Neuropathologica},
  year = {2024},
  doi = {10.1007/s00401-024-02712-2}
}
Kostenlos starten →